Skip to Content

Join the 'C1 Inhibitor (Human)' group to help and get support from people like you.

C1 Inhibitor (Human) News

FDA Approves Haegarda - First Subcutaneous C1 Esterase Inhibitor for Hereditary Angioedema

Posted 2 days 19 hours ago by Drugs.com

June 22, 2017 – The U.S. Food and Drug Administration today approved Haegarda, the first C1 Esterase Inhibitor (Human) for subcutaneous (under the skin) administration to prevent Hereditary Angioedema (HAE) attacks in adolescent and adult patients. The subcutaneous route of administration allows for easier at-home self-injection by the patient or caregiver, once proper training is received. HAE, which is caused by having insufficient amounts of a plasma protein called C1-esterase inhibitor (or C1-INH), affects approximately 6,000 to 10,000 people in the U.S. People with HAE can develop rapid swelling of the hands, feet, limbs, face, intestinal tract or airway. These attacks of swelling can occur spontaneously, or can be triggered by stress, surgery or infection. "The approval of Haegarda provides a new treatment option for adolescents and adults with Hereditary Angioedema," said Peter ... Read more

Related support groups: Hereditary Angioedema, Berinert, C1 Inhibitor (Human), Cinryze, Haegarda

FDA Approves Ruconest for Hereditary Angioedema

Posted 18 Jul 2014 by Drugs.com

July 17, 2014 – The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Hereditary angioedema, which is caused by having insufficient amounts of a plasma protein called C1-esterase inhibitor, affects approximately 6,000 to 10,000 people in the United States. People with HAE can develop rapid swelling of the hands, feet, limbs, face, intestinal tract, or airway. These acute attacks of swelling can occur spontaneously, or can be triggered by stress, surgery or infection. Swelling of the airway is potentially fatal without immediate treatment. “Hereditary angioedema is a rare and potentially life-threatening disease,” said Karen Midthun, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “Today’s approv ... Read more

Related support groups: Angioedema, Hereditary Angioedema, C1 Inhibitor (Human)

CSL Behring Receives FDA Approval of Expanded Label on Berinert for Self-administration and Treatment of Acute Laryngeal Attacks of Hereditary Angioedema

Posted 4 Jan 2012 by Drugs.com

Patients with rare, sometimes life-threatening condition can now treat themselves at home at the first sign of acute facial, abdominal or laryngeal swelling attacks KING OF PRUSSIA, Pa., Jan. 3, 2012 /PRNewswire/ – CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for self-administration of Berinert ®, C1 Esterase Inhibitor (Human),  a pasteurized, nanofiltered therapy indicated for the treatment of acute attacks of hereditary angioedema (HAE), a rare and potentially fatal genetic disorder. With appropriate training from a physician, patients can now self-administer Berinert by intravenous infusion. As part of the label expansion, Berinert is now also indicated to treat life-threatening laryngeal HAE attacks, as well as facial and abdominal attacks. "Once the early signs of an HAE attack begin to emerge, any delay in starting t ... Read more

Related support groups: Hereditary Angioedema, Berinert, C1 Inhibitor (Human)

Ask a Question

Further Information

Related Condition Support Groups

Hereditary Angioedema

Related Drug Support Groups

Berinert, Cinryze, Haegarda

C1 Inhibitor (Human) Patient Information at Drugs.com